基线[18F]FDG PET/CT与MRI乳腺肿瘤一阶特征不能改善新辅助化疗病理完全缓解预测
该回顾性研究纳入168例乳腺非特殊型浸润癌患者的170个肿瘤,评估基线[18F]FDG PET/CT提取的摄取值与异质性特征及T1加权动态增强MRI一阶特征对新增辅助化疗后病理完全缓解(pCR)的预测价值。结果显示,仅HER2阴性肿瘤中原发灶高摄取强度与高异质性及腋窝淋巴结高摄取强度与pCR相关,但多因素分析中PET或MRI特征均未在临床病理特征基础上增加pCR预测价值,唯一显著预测因素为雌激素受体状态、HER2表达和分级。
要点
- 在HER2阴性乳腺癌中,原发灶[18F]FDG高摄取强度与高异质性与新辅助化疗后pCR相关。
- HER2阴性乳腺癌pCR组腋窝淋巴结示踪剂摄取强度更高。
- PET或MRI乳腺肿瘤特征联合临床病理特征未额外改善pCR预测。
核心结论
- 除HER2阴性肿瘤外,基线原发灶及腋窝淋巴结[18F]FDG PET特征与新辅助化疗反应无关。
- 与病理特征相比,乳腺肿瘤提取的PET或MRI特征均未改善新辅助化疗反应预测。
研究设计与样本
- 回顾性研究纳入接受基线[18F]FDG PET/CT、新辅助化疗及手术的乳腺非特殊型浸润癌患者。
- 共纳入168例患者的170个肿瘤。
- 从原发乳腺癌及可疑腋窝淋巴结提取反映示踪剂摄取强度与异质性的PET特征,比较pCR与非pCR组。
- 采用多因素逻辑回归结合乳腺肿瘤PET特征与临床病理特征预测反应。
- 在103个肿瘤亚样本中,将乳腺肿瘤提取的MRI一阶特征加入多因素逻辑回归进行亚组分析。
主要发现
- 170个肿瘤中60个获得pCR(管腔B样20/107、三阴性25/45、HER2富集替代分子亚型15/18)。
- 在HER2阴性肿瘤(免疫组化评分0、1+或2+且原位杂交未扩增)中,原发灶[18F]FDG摄取强度更高和异质性更高与新辅助化疗反应相关。
- 在HER2阴性肿瘤中,pCR组腋窝淋巴结示踪剂摄取强度更高。
- 其他亚组分析中无[18F]FDG PET特征与pCR相关。
- 与临床病理特征联合时,[18F]FDG PET或MRI特征均未提供额外pCR预测价值,唯一显著预测因素为雌激素受体状态、HER2表达和分级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To verify the ability of pretreatment [18F]FDG PET/CT and T1-weighed dynamic contrast-enhanced MRI to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients. METHODS: This retrospective study includes patients with BC of no special type submitted to baseline [18F]FDG PET/CT, NAC and surgery. [18F]FDG PET-based features reflecting intensity and heterogeneity of tracer uptake were extracted from the primary BC and suspicious axillary lymph nodes (ALN), for comparative analysis related to NAC response (pCR vs. non-pCR). Multivariate logistic regression was performed for response prediction combining the breast tumor-extracted PET-based features and clinicopathological features. A subanalysis was performed in a patients' subsample by adding breast tumor-extracted first-order MRI-based features to the multivariate logistic regression. RESULTS: A total of 170 tumors from 168 patients were included. pCR was observed in 60/170 tumors (20/107 luminal B-like, 25/45 triple-negative and 15/18 HER2-enriched surrogate molecular subtypes). Higher intensity and higher heterogeneity of [18F]FDG uptake in the primary BC were associated with NAC response in HER2-negative tumors (immunohistochemistry score 0, 1 + or 2 + non-amplified by in situ hybridization). Also, higher intensity of tracer uptake was observed in ALN in the pCR group among HER2-negative tumors. No [18F]FDG PET-based features were associated with pCR in the other subgroup analyses. A subsample of 103 tumors was also submitted to extraction of MRI-based features. When combined with clinicopathological features, neither [18F]FDG PET nor MRI-based features had additional value for pCR prediction. The only significant predictors were estrogen receptor status, HER2 expression and grade. CONCLUSION: Pretreatment [18F]FDG PET-based features from primary BC and ALN are not associated with response to NAC, except in HER2-negative tumors. As compared with pathological features, no breast tumor-extracted PET or MRI-based feature improved response prediction.
引用
- Oliveira C, Oliveira F, Constantino C, et al. Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2024. PMID: 38922396. doi:10.1007/s00259-024-06815-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。